A Multi-site, Prospective Registry of Patients Undergoing Gastric Fundal Mucosal Ablation at True You Weight Loss
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Obesity
- Sponsor
- True You Weight Loss
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Percent Change in Total Body Weight Loss (TBWL) from Baseline
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The purpose of this study is to construct a multi-site, prospective registry to evaluate the clinical outcomes of patients who have undergone gastric fundus mucosal ablation at True You Weight Loss.
Detailed Description
Obesity is a chronic, progressive, multifactorial disease that contributes to increasing morbidity, mortality, and economic costs worldwide. The oxyntic mucosa of the gastric fundus is the principal site for the production of the orexigenic peptide hormone ghrelin. Ghrelin activates hunger-promoting pathways of the hypothalamus and opposes the satiety-promoting actions of other gastrointestinal peptides, leading to calorie-ingesting behaviors and weight gain. A method to reduce ghrelin production and decrease fundal compliance and capacity through mucosal devitalization may confer benefit to patients seeking treatment for obesity. This is a multi-site, prospective registry of patients who have elected to undergo Gastric Fundus Mucosal Ablation (GFMA) at a True You Weight Loss site in Cary, NC or Atlanta, GA. Study participants will consist of up to 200 adult patients of ages 18 to 65 years old who have elected to undergo GFMA at a True You Weight Loss site (Cary, NC or Atlanta, GA) prior to their involvement in the study. Participants that meet the criteria below will be deemed eligible for participation after consultation with the study investigator. Study participants will receive follow-up care according to standard of care practices, regardless of their involvement in the research study. Standard of care nutritional practice includes a comprehensive lifestyle program with long-term nutritional support and monitoring. Patient weights and adverse events will be collected at each visit. Adverse events will be communicated to medical team members in between dedicated visits. We aim to establish a multi-site, prospective registry to longitudinally describe GMFA in adults with obesity, including patient characteristics, weight loss, improvement in weight-related medical conditions, and adverse events.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age ≥ 18 years and ≤ 65 years old
- •BMI ≥ 27 and ≤55 kg/m²
- •Willingness to comply with the substantial lifelong dietary restrictions required by the procedure.
- •Ability to give informed consent
- •Women of childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods.
- •Those who plan to receive the gastric fundus mucosal ablation procedure at True You Weight Loss regardless of the research
Exclusion Criteria
- •Patients that do not meet eligibility requirements for the study as per the Principal Investigator's standard selection criteria
- •Active psychological issues preventing participation in a life-style modification program as determined by a psychologist.
- •Patients who are pregnant or breast-feeding.
- •Eating disorders including night eating syndrome (NES), bulimia, binge eating disorder, or compulsive overeating.
- •Patients with previous or current tobacco use
- •Patients with prior gastric surgery (e.g., vertical sleeve gastrectomy, gastric bypass, hiatal hernia repair, Nissen fundoplication, adjustable gastric band).
- •Patients on therapeutic anticoagulation or antithrombotics that cannot be interrupted for at least 12 weeks following GFMA.
- •Patients who cannot commit to 12 weeks of post-GMFA pharmacologic ulcer prophylaxis
- •At the discretion of the PI for subject safety
Outcomes
Primary Outcomes
Percent Change in Total Body Weight Loss (TBWL) from Baseline
Time Frame: 12 Months
Measured percent change in total body weight over time following Gastric Fundus Mucosal Ablation. %TBWL = (pre-op weight - post op body weight) / (pre-op weight) \* 100 measured as a percentage.
Secondary Outcomes
- Percent Change in Total Body Weight Loss (TBWL) from Baseline(3 Months, 6 Months, 9 Months, 12 Months, 15 Months, 24 Months)
- Change in Body Mass Index (BMI) from Baseline(3 Months, 6 Months, 9 Months, 12 Months, 15 Months, 24 Months)
- Percent Excess Weight Loss from Baseline (EWL)(3 Months, 6 Months, 9 Months, 12 Months, 15 Months, 24 Months)